- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00738335
Stereotactic Radiosurgery and Erlotinib in Treating Patients With Non-Small Cell Lung Cancer and Brain Metastases
A Phase I Open-Label, Dose-Finding Study to Evaluate the Safety and Efficacy of Concurrent Radiosurgery and Erlotinib Administration in Non-Small Cell Lung Cancer Patients With Brain Metastases
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Stereotactic radiosurgery may be able to deliver x-rays directly to the tumor and cause less damage to normal tissue. Erlotinib may make tumor cells more sensitive to radiation therapy. Giving erlotinib together with stereotactic radiosurgery may kill more tumor cells.
PURPOSE: This phase I clinical trial is studying the side effects of erlotinib when given together with stereotactic radiosurgery and to see how well it works in treating patients with non-small cell lung cancer with brain metastases.
Visão geral do estudo
Status
Condições
Descrição detalhada
OBJECTIVES:
Primary
- To determine the acute as well as long-term toxicity (especially grade III neurotoxicity) of concurrent erlotinib hydrochloride and single-fraction radiosurgery in patients with non-small cell lung cancer (NSCLC) and brain metastases.
Secondary
- To determine the freedom from progression in all detected lesions (i.e., radiosurgically treated and untreated) and the rate of response of radiosurgically treated lesions in patients receiving concurrent erlotinib hydrochloride and radiosurgery as compared with historical controls treated with gamma knife radiosurgery alone at UCSF.
- To measure the rate of freedom from any CNS progression in these patients at 1 year post treatment.
- To assess cerebrospinal fluid (CSF) distribution of erlotinib hydrochloride by measuring both erlotinib hydrochloride and its major metabolite, OSI-420, in plasma and CSF at 4 or more days after initial erlotinib hydrochloride administration but before radiosurgery, and again at 4 weeks after stereotactic radiosurgery (optional).
- To perform CSF and serum biomarker analysis for NSCLC using 2-dimensional liquid chromatography or mass spectrometry (2D-LC/MS).
- To determine the incidence of subclinical leptomeningeal disease in patients assigned to gamma-knife treatment and who do not exhibit signs or symptoms or carcinomatous meningitis.
OUTLINE: Patients receive oral erlotinib hydrochloride once daily for at least 7 days. Patients then undergo stereotactic radiosurgery on day 0. Beginning the day after radiosurgery, patients receive erlotinib hydrochloride once daily for 4 weeks in the absence of disease progression or unacceptable toxicity. After completion of study therapy, patients may continue to receive erlotinib hydrochloride at the discretion of their oncologist.
Patients undergo cerebrospinal fluid (CSF) and blood sample collection at baseline (at least 4 days after starting erlotinib hydrochloride and prior to radiosurgery) for pharmacokinetic and biomarker correlative studies. Samples are analyzed for concentrations of erlotinib hydrochloride by 2-dimensional-liquid chromatography/mass spectrometry and antithrombin by enzyme-linked immunosorbent assay.
After completion of study therapy, patients are followed every 3 months for 1 year.
Tipo de estudo
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
California
-
San Francisco, California, Estados Unidos, 94115
- UCSF Helen Diller Family Comprehensive Cancer Center
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
DISEASE CHARACTERISTICS:
Histologically confirmed non-small cell lung cancer (NSCLC) meeting the following criteria:
Fewer than 5 intraparenchymal brain metastases by gadolinium-enhanced MRI meeting the following criteria:
Maximum diameter ≤ 4.0 cm
- If multiple lesions are present and one lesion is > 3.0 cm, the remaining lesions must be ≤ 3.0 cm in maximum diameter
- No metastases within 3 mm of the optic nerve or optic chiasm such that some portion of the optic nerve or chiasm would receive > 9 Gy from radiosurgery
- No metastases in the brainstem, midbrain, pons, or medulla
No prior complete resection of a single brain metastasis or of all known brain metastases
- Subtotal resection allowed provided residual disease is ≤ 4.0 cm in maximum diameter
No clinical or radiographic evidence of unstable systemic progression (other than the study lesion[s]) within the past month
- Patients with brain metastases at initial presentation do not require 1 month of scans documenting stable disease
- Isolated brain metastases with stable systemic disease allowed
- No leptomeningeal metastases by MRI and/or positive cerebrospinal fluid cytology
PATIENT CHARACTERISTICS:
- Karnofsky performance status 60-100%
- Life expectancy ≥ 3 months
- ANC > 1,000/mm³
- Platelet count > 100,000/mm³
- Hemoglobin > 10 g/dL
- PT and PTT normal
- AST < 2 times upper limit of normal (ULN)
- Alkaline phosphatase < 2 times ULN
- Total bilirubin < 2 times ULN
- Lactic dehydrogenase < 2 times ULN
- Serum creatinine < 1.5 times ULN
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for ≥ 2 weeks after completion of study therapy
- Neurologic function status 0-2
- No history of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinib hydrochloride
- No contraindication to MRI (e.g., cardiac pacemaker)
- No absolute contraindication to lumbar puncture
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- Prior systemic therapy allowed
No prior cranial radiotherapy
- Prior radiotherapy to noncranial sites allowed
- More than 1 week since prior intrathecal chemotherapy or prior treatment of leptomeningeal carcinoma
No concurrent systemic therapy
- Prior or current erlotinib hydrochloride for treatment of systemic disease allowed provided systemic disease has not progressed while on erlotinib hydrochloride
No concurrent enzyme-inducing anticonvulsant
- If patients are on an enzyme-inducing anticonvulsant (e.g., phenytoin, carbamazepine, or phenobarbital), the agent must be converted to a nonenzyme-inducing anticonvulsant before or at the start of erlotinib hydrochloride treatment
- No concurrent CYP3A4 inhibitors or inducers (e.g., Hypericum perforatum [St. John wort] or ketoconazole)
- No other concurrent investigational therapy
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
---|
Acute and long-term toxicity (i.e., neurotoxicity, gastrointestinal, cutaneous, and hematologic) as assessed by NCI CTCAE v3.0.
|
Medidas de resultados secundários
Medida de resultado |
---|
Progressão da doença
|
Response rate of radiosurgically treated lesions in patients receiving concurrent erlotinib hydrochloride and radiosurgery on this study vs the response rate of historical controls previously treated with gamma knife radiosurgery alone
|
CNS progression at 1 year
|
Distribution of erlotinib hydrochloride in plasma and cerebrospinal fluid (CSF)
|
CSF and serum biomarkers
|
Incidence of subclinical leptomeningeal disease
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: James L. Rubenstein, MD, PhD, University of California, San Francisco
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças Cerebrais
- Doenças do Sistema Nervoso Central
- Doenças do Sistema Nervoso
- Doenças Respiratórias
- Neoplasias
- Doenças pulmonares
- Neoplasias por local
- Neoplasias do Trato Respiratório
- Neoplasias Torácicas
- Carcinoma Broncogênico
- Neoplasias Brônquicas
- Neoplasias do Sistema Nervoso Central
- Neoplasias do Sistema Nervoso
- Neoplasias Pulmonares
- Carcinoma pulmonar de células não pequenas
- Neoplasias Cerebrais
- Mecanismos Moleculares de Ação Farmacológica
- Inibidores Enzimáticos
- Agentes Antineoplásicos
- Inibidores de proteína quinase
- Cloridrato De Erlotinibe
Outros números de identificação do estudo
- CDR0000612064
- UCSF-072520
- CC# 072520
- GENENTECH-UCSF-072520
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Câncer de pulmão
-
University of LorraineConcluídoCriança, Somente | Pneumotórax espontâneo | Pneumotórax idiopático | Bleb LungFrança
-
Assiut UniversityAinda não está recrutandoCâncer de pulmão | Lesão pulmonar | Bleb Lung
-
Turku University HospitalLounais-Suomen SyöpäyhdistysAinda não está recrutandoSobrevivente de cancerFinlândia
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RetiradoSobrevivente de cancerEstados Unidos
-
University of Alabama at BirminghamNational Cancer Institute (NCI); Auburn UniversityConcluído
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)ConcluídoSobrevivente de cancerEstados Unidos
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)ConcluídoSobrevivente de cancerEstados Unidos, Guam
-
Wake Forest University Health SciencesNational Cancer Institute (NCI); National Institute of Mental Health (NIMH)ConcluídoSobrevivente de cancerEstados Unidos
-
Masonic Cancer Center, University of MinnesotaConcluídoSobrevivente de cancerEstados Unidos
-
University of New MexicoNew Mexico State University; University of New Mexico Cancer CenterConcluído
Ensaios clínicos em estudo farmacológico
-
Radicle ScienceConcluídoEstresse | AnsiedadeEstados Unidos
-
Apple Inc.Stanford UniversityConcluídoFibrilação atrial | Arritmias Cardíacas | Flutter AtrialEstados Unidos
-
Radicle ScienceAtivo, não recrutandoDistúrbio do sono | Dorme | Distúrbios de sonoEstados Unidos
-
Radboud University Medical CenterUCB Pharma; Verily Life Sciences LLCRecrutamentoDoenças Cerebrais | Distúrbios do Movimento | Doenças Neurodegenerativas | Paralisia Supranuclear ProgressivaHolanda
-
Radboud University Medical CenterUCB Pharma; Verily Life Sciences LLCRecrutamentoDoenças Cerebrais | Doenças do Sistema Nervoso Central | Doenças do Sistema Nervoso | Doença de Parkinson | Distúrbios parkinsonianos | Doenças dos Gânglios da Base | Distúrbios do Movimento | Doenças NeurodegenerativasHolanda
-
University of MichiganConcluído
-
University of MichiganConcluído
-
Nexilis AGRescindidoFratura osteoporótica da vértebraÁustria
-
Radicle ScienceAtivo, não recrutandoEstresse | AnsiedadeEstados Unidos
-
Digisight Technologies, Inc.DesconhecidoRetinopatia diabética | Idade - Degeneração Macular Relacionada | MetamorfopsiaEstados Unidos